Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT01165268
- Locations
- 🇺🇸
Profil Institute For Clinical Research, Inc., Chula Vista, California, United States
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker
- Conditions
- Interventions
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2996
- Registration Number
- NCT01137474
- Locations
- 🇺🇸
Arcuri Clinical Research Llc, Philadelphia, Pennsylvania, United States
🇺🇸Philadelphia Health Associates - Adult Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Cedar Crosse Research Center, Chicago, Illinois, United States
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT01135446
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
- Conditions
- Interventions
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1179
- Registration Number
- NCT01095653
- Locations
- 🇨🇳
Local Institution, Yung Kang city, Taiwan
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
- Conditions
- Interventions
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1484
- Registration Number
- NCT01095666
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT01072578
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT01068756
- Locations
- 🇺🇸
Ppd Development, Austin, Texas, United States
A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets
- Conditions
- Interventions
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT01055691
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT01055652
- Locations
- 🇯🇵
Research Site, Osaka, Japan
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
- Conditions
- Interventions
- First Posted Date
- 2010-01-06
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 964
- Registration Number
- NCT01042977
- Locations
- 🇵🇱
Research Site, Zielona Gora, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.